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Background—Molecular diagnostics enable sensitive detection of respiratory viruses, but their 
clinical significance remains unclear in pediatric lower respiratory tract infection (LRTI). We 
aimed to determine whether viral coinfections increased life-threatening disease in a large cohort.
Methods—Molecular testing was performed for respiratory viruses in nasopharyngeal aspirates 
collected from children aged <5 years within 24 hours of hospital admission during sentinel 
surveillance for severe acute respiratory illness (SARI) hospitalization conducted in South Africa 
during February 2009–December 2013. The primary outcome was life-threatening disease, defined 
as mechanical ventilation, intensive care unit admission, or death.
Results—Of 2322 HIV-uninfected children with respiratory syncytial virus (RSV)–associated 
LRTI, 1330 (57.3%) had RSV monoinfection, 38 (1.6%) had life-threatening disease, 575 (24.8%) 
had rhinovirus, 347 (14.9%) had adenovirus (ADV), and 30 (1.3%) had influenza virus. RSV and 
any other viral coinfection was not associated with severe disease (odds ratio [OR], 1.4; 95% 
confidence interval [CI], OR, 0.74; 95% CI, .39–1.4), ADV coinfection had increased odds of life-
threatening disease (adjusted OR, 3.4; 95% CI, 1.6–7.2; P = .001), and influenza coinfection had 
increased odds of life-threatening disease and prolonged length of stay (adjusted OR, 2.1; 95% CI, 
1.0–4.5; P = .05) compared with RSV monoinfection.
Conclusions—RSV coinfection with any respiratory virus is not associated with more severe 
disease when compared to RSV alone in this study. However, increased life-threatening disease in 
RSV-ADV and RSV-influenza coinfection warrants further study.
Keywords
respiratory syncytial virus; viral coinfection; lower respiratory tract infection disease severity
Respiratory syncytial virus (RSV) is a global health problem, causing an estimated 66 000–
199 000 deaths per year globally in children <5 years of age [1]. The clinical manifestations 
of RSV infection range widely from a mild, self-limiting upper respiratory tract infection 
(URTI) to severe lower respiratory tract infection (LRTI), which may lead to death. Risk 
factors for severe disease include premature birth, low birth weight, immunocompromised 
status, chronic lung disease, congenital heart disease, human immunodeficiency virus (HIV) 
infection, and Down syndrome [2–8]; however, the majority of infants hospitalized for RSV 
LRTI are previously healthy children [9].
Currently, management options for RSV-associated disease are limited, with supportive 
treatment as the cornerstone of clinical care [10]. Therefore, it is essential to gain insight 
into factors contributing to disease severity to effectively direct future preventive and 
therapeutic interventions.
The development of sensitive molecular diagnostics for the detection of respiratory viruses 
has given insight into the viral respiratory dynamics during severe respiratory infection [11]. 
There are conflicting data on whether viral coinfection results in more severe RSV-
associated LRTI. Whereas some studies report an association for RSV–human 
metapneumovirus (HMPV) coinfection and less severe disease [12–14], others report more 
severe disease associated with RSV-HMPV, RSV-rhinovirus (RV), RSV-adenovirus (ADV), 
and any coinfection compared to identification of RSV alone [15–21]. Furthermore, no 
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association with disease severity for RSV-RV, RSV-HMPV, and any viral coinfection has 
been reported by others [13, 22–25]. The majority of these studies are limited by assessment 
over a single season [15, 18, 26], lack of adjustment for confounders [13,15,20,22–25], and 
small sample size (38–666 RSV cases), all of which could bias the interpretation of the 
results.
The aim of this study was to evaluate the effect of respiratory viral coinfection on disease 
severity among children hospitalized with RSV-associated LRTI.
METHODS
Study Site, Design, and Population
Children <5 years of age hospitalized with severe acute respiratory illness (SARI) were 
enrolled in a prospective, hospital-based, sentinel surveillance study conducted at 6 sites in 4 
provinces in South Africa from February 2009 through December 2013 as described 
elsewhere [27]. Four rural, periurban, and urban hospital sites enrolled children in 3 
provinces (Gauteng, Mpumalanga, KwaZulu-Natal), and 2 sites were added in a fourth 
province (North West) in June 2010. There were a total of 24 pediatric intensive care unit 
(ICU) beds available across all sites.
Data Collection and Case Definition
SARI was defined among hospitalized children as follows: physician-diagnosed sepsis or 
LRTI in children aged 2 days to 3 months; or physician-diagnosed LRTI in children aged 3 
months to 5 years, presenting within 7 days of symptom onset. Exclusion criteria were 
transfer from another hospital, neonates who were never discharged after delivery, and 
children residing outside of the hospital catchment area. A nasopharyngeal aspirate (NPA) in 
4 mL of normal saline and a blood sample were collected from the child, ideally within 24 
hours of admission but up to 7 days after onset of symptoms. Specimens were transported 
within 72 hours of collection to the National Institute for Communicable Diseases in 
Johannesburg for viral and bacterial analysis. Demographic and hospitalization data were 
collected by interview and record review, and children were followed up to hospital 
discharge.
Laboratory Testing
RSV infection was confirmed via multiplex real-time reverse-transcription polymerase chain 
reaction (PCR) assay performed on collected NPAs. NPAs were also tested for 9 other 
viruses: ADV, parainfluenza viruses 1, 2, and 3 (PIV1–3), influenza A and B viruses, 
HMPV, RV, and enterovirus (EV) with the same molecular testing technique [28]. RV clades 
A, B, and C were detected in the primer set utilized [29]. ADV testing was not done from 
August to October 2009 due to limited availability of reagents [28]. PCR data were 
semiquantitative and specimens with a cycle threshold (Ct) value <37 were considered 
positive. To detect pneumococcal infection, both blood culture for Streptococcus 
pneumoniae and whole blood lytA PCR were performed on blood specimens, although 
blood cultures were not systematically performed on all patients [30]. HIV testing was 
performed on a whole blood specimen or dried blood spot using an HIV PCR assay for 
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children <18 months of age and HIV enzyme-linked immunosorbent assay for children ≥18 
months of age. Quality Control for Molecular Diagnostics external quality assessments for 
all viruses in the panel were performed as well as annual World Health Organization panels 
for influenza alongside live and post hoc data quality checks.
Outcomes
The primary outcome of this study, life-threatening disease, was defined as a composite 
outcome of mechanical ventilation, ICU admission, or death. The secondary outcome was 
life-threatening disease or prolonged length of hospital stay ≥5 days.
Statistical Analyses
Continuous variables were described using mean (standard deviation) or median 
(interquartile range [IQR]). Differences in mean/median of continuous variables were tested 
with the 2-sided t test or a nonparametric Mann-Whitney test when appropriate. Categorical 
variables were described with frequencies and percentages and compared between groups 
using χ2 test or Fisher exact test if there were <5 observations in one group.
Logistic regression was used to assess the association between any viral coinfection (at least 
one of the following viruses detected: HMPV, RV, ADV, EV, influenza, PIV1, PIV2, PIV3) 
and virus-specific coinfections on the study outcomes as described above among RSV-
positive children. In addition, we compared ADV-RSV and influenza-RSV coinfections to 
ADV and influenza monoinfection, as coinfection with these pathogens among RSV-positive 
children was found to be associated with increased risk of life-threatening disease. This 
analysis was implemented to assess whether ADV and influenza monoinfection were the 
driver of severe disease. Results were expressed as odds ratios (ORs) with 95% confidence 
intervals (CIs). Multivariate logistic regression was performed by use of the manual forward 
stepwise procedure including variables with a P value < .2 in univariate analyses. The 
analysis was adjusted for age using the subgroups <6 months and ≥6 months. The primary 
analysis was conducted on the HIV-uninfected population; subsequently, a separate analysis 
was performed for the HIV-infected population due to significantly elevated mortality rate 
and altered immune status of this subgroup.
We considered P < .05 to be significant for all analyses. Statistical analysis was performed 
using STATA/SE software, version 13.1 (StataCorp, College Station, Texas).
Ethical Considerations
The study protocol was approved by the University of the Witwatersrand Ethics Committee 
and the KwaZulu-Natal Human Biomedical Research Ethics Committee (protocol M081042 
and BF157/08). Details of consenting, which included written informed consent from the 
parent or primary caregiver of the child, have been described [30]. This surveillance was 
deemed nonresearch by the US Centers for Disease Control and Prevention (NRD 2012 
6197).
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RESULTS
Study Population
During February 2009 to December 2013, 10 128 children <5 years of age were enrolled, 
including 2404 (23.7%) with RSV-associated LRTI. Our total HIV-uninfected population 
with RSV-associated LRTI was 2322 children. We performed a sensitivity analysis to 
validate HIV status and found that the untested and HIV-negative population did not differ in 
baseline characteristics or underlying conditions, and both had a similar mean RSV Ct value 
of 25.1 (SD, 5.1) and 25.7 (SD, 4.6) (P = .004), respectively (Supplementary Table 1).
Prevalence of Viral Coinfection
Table 1 details the prevalence of respiratory virus coinfections among children hospitalized 
for RSV-associated LRTI, including stratification by age groups <6 months and ≥6 months 
of age. The prevalence of any respiratory viral coinfection was more common among 
children aged ≥6 months (529 [51.1%]) compared with those aged <6 months (463 [36.0%]) 
(P < .001). The prevalence of RSV-PIV1, RSV-PIV2, and RSV-PIV3 coinfection was <1% 
in both groups. Rhinovirus was the most prevalent coinfecting virus, found among 23.5% of 
children aged <6 months and 26.4% of children aged ≥6 months; followed by RSV-ADV 
coinfection (8.3% and 23.2% in children aged <6 months and ≥6 months, respectively; P < .
001) and RSV-EV coinfection (5.6% and 11.5% in children aged <6 months and ≥6 months, 
respectively; P <.001). The different permutations of viral coinfections in the RSV-infected 
population are elucidated in a coinfection matrix (Supplementary Table 2).
We compared the prevalence of viruses in the presence (n = 2404) or absence of RSV (n = 
7447) and found that the presence of RSV was associated with a lower prevalence of all 
other respiratory viruses during RSV season (Supplementary Figure 1). In the RSV-negative 
population, 19.3% (1436/7447) of children hospitalized for LRTI had 2 or more viruses 
detected in the respiratory tract, with the most prevalent viruses being RV and ADV, 
respectively.
Demographic and Clinical Characteristics
We examined the prevalence of demographic and clinical characteristics among RSV 
monoinfection cases and those with any respiratory virus coinfection, stratified by age <6 
months and ≥6 months. A total of 1287 children were aged <6 months and 1035 were aged 
≥6 months. The median age for RSV monoinfection was 4.2 months (IQR, 1.9–9.6 months), 
and 6.6 months (IQR, 3.0–14.7 months) for RSV with any viral coinfection. Age was 
associated with RSV and any viral coinfection in both children <6 months of age (P < .001) 
and aged ≥6 months (P = .05; Table 2).
We described the demographics and underlying conditions of RSV monoinfection and 
coinfections in Table 2. Underlying conditions were not more prevalent in viral coinfection 
than in RSV monoinfection (P = .29 for children aged <6 months; P = .38 for children aged 
≥6 months).
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Respiratory Viral Coinfections and Disease Severity
Within the RSV-positive population <5 years old, 26 children (1.1%) were admitted to the 
ICU, 21 children (0.90%) needed mechanical ventilation, and 8 children died (0.34%). 
Seventeen of the 21 children (81%) who received mechanical ventilation were admitted to 
the ICU. Sixty-seven percent of children were hospitalized for <5 days. When comparing 
RSV with any respiratory viral coinfection to RSV monoinfection, we found no overall 
association between any viral infection and life-threatening disease (OR, 0.74; 95% CI, .39–
1.4; P = .36; Table 3). We found the same to be true for our secondary outcome, including 
extended length of stay (adjusted OR [aOR], 0.83; 95% CI, .69–1.0; P = .05) Table 4. After 
adjusting for confounders, RSVADV coinfection had a 3.4 increased odds of life-threatening 
disease compared with RSV monoinfection (95% CI, 1.6–7.2; P = .001; Table 3). RSV-ADV 
coinfection was not associated with the secondary outcome (aOR, 1.0; 95% CI, 0.77–1.3; P 
= .77, Table 4). When we compared RSV-ADV coinfection to ADV monoinfection, we 
found no relation to life-threatening disease (aOR, 0.78; 95% CI, .37–1.6; P = .51) and 
decreased life-threatening disease and extended length of stay (aOR, 0.51; 95% CI, .38–.70; 
P < .001). The median ADV Ct value was significantly lower in ADV monoinfection (29.7; 
IQR, 20.8–34.3) compared with RSV-ADV infection (33.2; IQR, 30.1–35.5) (P < .001). 
Finally, RSV-influenza showed increased odds for our secondary outcome including 
prolonged length of stay (aOR, 2.1; 95% CI 1.0–4.5; P = .05) Table 4. We identified an 
increased odds of our secondary outcome for RSV-influenza when compared to influenza 
alone (aOR, 2.1; 95% CI, 1.0–4.4; P = .04). No other viral coinfections showed increased 
odds of severe disease compared with RSV monoinfection.
In the HIV-infected population, 6.3% (n = 5) of children had life-threatening disease. Mean 
RSV Ct value was significantly lower in the HIV-infected population than the HIV-
uninfected population (RSV Ct value 27.1 [SD, 5.0] vs 25.5 [SD, 4.8]; P = .003). Similarly, 
in this population, we found no association between any viral coinfection and more severe 
disease compared with RSV monoinfection [Supplementary Table 4].
RSV Viral Load and Disease Severity
We found a mean Ct value of 25.1 (SD, 4.6) for children aged <6 months and 26.0 (SD, 5.0) 
for children aged ≥6 months (P < .001). RSV viral load was not associated with life-
threatening disease in children with RSV monoinfection or children with RSV with any 
coinfection. When included in our multivariate model, RSV Ct values were not found to be 
associated with life-threatening disease (aOR, 1.0; 95% CI, .94–1.1) or the secondary 
outcome including increased length of stay (aOR, 1.0; 95% CI, .98–1.0).
DISCUSSION
In general, our study did not corroborate the findings from previous smaller studies, that 
children hospitalized with LRTI characterized by RSV coinfection with respiratory viruses 
had more severe disease compared with children with RSV monoinfection [15, 31, 32]. We 
did, however, identify an association between RSV-ADV coinfection and life-threatening 
disease, which may be indicative of synergistic pathogenesis leading to respiratory failure or 
that severe disease in these children was largely driven by coinfection with ADV. The 
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association of RSV-ADV coinfection with severe disease was, however, not evident when we 
assessed prolonged hospitalization. Our data are supported by findings of another study in 
which RSV-ADV coinfection showed statistically significant increases in hospital length of 
stay, days with supplemental oxygen use, ICU admission, and mechanical ventilation 
compared with RSV monoinfection in children hospitalized for LRTI, although no 
comparison was made with ADV monoinfection [33]. In a study of mixed RSV-ADV 
infection, RSV-ADV coinfection was not found to be more severe than ADV alone when 
examining duration of fever, oxygen requirement, and length of hospital stay [34]. Another 
study of 9 RSV-confirmed infants found that 75% of children with RSV-ADV coinfection 
died despite mechanical ventilation [35]. Even though ADV alone may be responsible for 
more severe disease, clinical features such as hospital stay were not found to differ between 
RSV and ADV hospitalized LRTI [36]. However, increased pathogenicity may be explained 
by distinctly different immunological responses produced by RSV and ADV. ADV induces 
interferon-γ production activating the classical antiviral defense mechanism and heightened 
mononuclear cell activation compared with RSV, possibly leading to more severe disease 
with coinfection [37].
The increased odds of severe disease for RSV-ADV coinfection may warrant further 
exploration on a host and pathogen level. Virus–virus interactions can be classified into 3 
categories [1]: viral genes or gene products interacting directly [2], host environment 
changes that result in indirect interaction, or [3] immunological interactions [38]. It is 
plausible that similar mechanisms that enhance bacterial superinfection may also enhance 
viral superinfection, namely, depletion of host defenses due to initial viral infection [39].
We found that coinfection of RSV and any other virus was not related to disease severity. 
This is in line with a retrospective study which found that clinical severity did not differ 
between RSV monoinfection and viral coinfection with 17 different respiratory viruses [40]. 
A recent meta-analysis of clinical disease severity and viral coinfection vs monoinfection 
found no clinical difference in severity between these 2 groups even when constrained to 
more pathogenic respiratory viruses (influenza, RSV, HMPV, PIV) [19]. Another meta-
analysis of single and multiple virus respiratory infections (influenza, RV, ADV, HMPV, 
coronavirus, bocavirus, PIV1–3) and severity of disease concluded that the influence of 
coinfection on disease severity remains unclear due to the heterogeneity of results [41].
In our study, the highest prevalence of viral coinfection was detected in HIV-uninfected 
children aged ≥6 months hospitalized for LRTI. This is in accordance with findings from a 
number of studies that found multiple viral respiratory infection to be associated with older 
age [21, 33, 42, 43] when compared to RSV monoinfection. Increased rates of virus 
infection with increasing age have been described previously in this surveillance population 
[30]. The increased prevalence of respiratory viral coinfections among children aged ≥6 
months may be explained by increased exposure to respiratory viruses, an increased immune 
response during primary infection that discourages viral coinfection, or increased 
susceptibility due to waning maternal antibodies [44].
In the presence of RSV, our data show lower prevalence of non-RSV viruses in children 
hospitalized for viral respiratory illnesses during the RSV season (Supplementary Figure 1). 
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This could be indicative of viral interference in which the presence of RSV in the 
community inhibits infection by or circulation of other viruses. Evidence of viral 
interference has been found in studies of children who received influenza vaccine [45, 46] 
and among children receiving immunoprophylaxis for RSV [47]. In both groups, the 
prevalence of nonpreventively targeted viruses was higher than among comparison groups 
that did not receive vaccination or immunoprophylaxis. However, these speculations and the 
clinical relevance of some of these identified viruses need further exploration with a more 
suitable study design.
The strength of this study lies in the large sample size, which allowed us to look at different 
permutations of coinfection within the RSV population and compare them to RSV 
monoinfection only and to draw conclusions about an infrequent, yet important, outcome. 
Furthermore, we were able to control for important confounders of disease severity 
including age and prematurity. Finally, we did not limit our assessment of respiratory viral 
coinfection to a single season.
There were some limitations to our study. Given that viral data were collected at one time 
point after disease onset, it is difficult to link viral detection to etiology of LRTI. Some 
respiratory viruses are frequently detected in asymptomatic children and infants. RSV, 
HMPV, influenza, and ADV are significantly more prevalent in symptomatic children, 
whereas RV is commonly found in asymptomatic individuals [48]. Another study of infants 
up to 12 months of age found that detection of RSV, RV, influenza, ADV, and HMPV are 
highly associated with symptoms, with an OR >4 for presence of symptoms, whereas for 
EV, detection is not significantly associated with symptoms [49]. In South Africa, ADV was 
only moderately associated with severe disease as it was commonly identified in controls; 
the attributable fraction of ADV detection was 10.1% [50]. Viral detection may also be an 
artefact of prolonged viral shedding: ADV, for example, is known to exhibit longer low-level 
shedding [51]. In the RSV-ADV coinfection population, we found more frequent low-level 
virus than in the population with ADV monoinfection, which may be indicative of prolonged 
viral shedding and acute infection, respectively (Figure 1). The multiplex PCR used was 
limited in its ability to discriminate between RV and EV due to cross-reactivity; therefore, 
these coinfections are not optimally characterized within this population. Furthermore, the 
definition of any viral coinfection is limited by the respiratory viruses we did not test for, 
although the clinical significance of many of those (eg, human coronavirus and human 
bocavirus) as LRTI etiological agents also remain to be fully elucidated. Another limitation 
was that we only had semiquantitative data for viral load.
CONCLUSIONS
The present study contributes to a better understanding of the role of viral coinfection in 
children hospitalized for RSV-associated LRTI. Molecular diagnostics for respiratory viruses 
may serve as an important diagnostic tool in pediatric LRTI, but the possible synergy of 
multiple viruses in the respiratory tract is an area with no clear consensus. In our study, we 
found that RSV and any respiratory viral coinfection was not associated with more severe 
disease. The association between RSV-ADV coinfection and life-threatening disease in 
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hospitalized children <5 years of age warrants further exploration and may be explained by 
enhanced ADV disease alone.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Histogram of adenovirus cycle threshold (Ct) values in human immunodeficiency virus-
uninfected children <5 years of age with adenovirus (ADV) monoinfection and those with 
respiratory syncytial virus (RSV)–ADV coinfection at 6 sentinel sites in South Africa, 2009–
2013.
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